Skip to main content

Table 3 Markers reduction ≥ 20% over baseline and tumor response (R)

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

  No-R
n (%)
R
n (%)
p-value
CEA reduction ≥ 20%
No 23 (88.5) 13 (56.5) 0.021
Yes 3 (11.5) 10 (43.5)
CYFRA21-1 reduction ≥ 20%
No 24 (92.3) 9 (37.5) < 0.001
Yes 2 (7.7) 15 (62.5)
NSE reduction ≥ 20%
No 17 (73.9) 11 (52.4) 0.21
Yes 6 (26.1) 10 (47.6)